Current Market Trends and Advancements in the Personalized Cancer Vaccine Segment
The treatment of cancer through the aspect of using vaccine that has been personalized according to the requirement with an approach that the therapy will provide no harm in the future is innovative yet challenging. The concept of personalized vaccine is recognized as a paradigm shift for the way the cancer is treated and the way cancer is seen in the future. Although many other therapies are available in the present for the treatment of cancer but majority of the therapies come with their own drawbacks and undesirable outcomes.
Personalized vaccine allows us to take a giant step towards the treatment of cancer as in each person’s cancer the case is different and the therapy is customized according to the individual cancer scenario. Personalized vaccines when compared with the already existing therapies, has accomplished a great success, with respect to the wide utilization of the treatment in different cancer types. The idea of fitting every cancer patient to the limited drugs has come to an end with the participation of this novel therapeutics into the active field of oncology.
The therapy approaches the development of a neoantigen vaccine that stimulates the immune system to attack the malignant cells in a unique way. Currently, the personalized cancer vaccine of immunotherapy segment is undergoing rapid advancements and improvements with the help of highly skilled researchers at the top universities and laboratories all around the world. Recent research published by some leading science journals reported excellent and emerging outcomes about the cancer vaccines. The current study about the segment is limited to lab animals, but once the testing is over, it will be tested in humans for the first time.
A number of clinical trials regarding the investigational therapy are currently mid-way of becoming the future of the cancer therapies. In the current scenario, USA and Europe are leading the race of having the major market players. Increasing adoption to healthcare system and advancements in the genome sequencing techniques are the major contributors to the huge market share in the region.
The research and development of personalized vaccine is supported by both private as well as public sectors by rising their investments in the personalized cancer vaccine segment. The advantage of increasing fundings can provide a valuable option to the patients as well as the research sector. CureVac, Kite pharma, Alphabet, Modema and Merck are some of the major investors in the personalized cancer vaccine segment. The development made by the researchers play an important role in setting up newly available treatments as they will contribute significantly to the cancer treatment and driving the market size by many folds.
The idea behind the development of personalized vaccine is an exception from all the cancer treatments that we all are dependent on. As per report findings, personalized vaccine is successful in showing tremendous progress in the research area and in future it will be a promising approach for treating certain tumors and other inflammatory diseases related with cancer. In the upcoming years, increasing number of cancer patients is expected to increase the market size and revolutionize the entire market for cancer therapies available.
This report on the personalized cancer vaccine market provides a comprehensive insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2026.
1. Personalized Cancer Vaccine: Revolutionizing the Immunotherapeutics of the Future
1.1 The Approach Towards Cancer Vaccine Strategy 1.2 Cancer Vaccines - Current Clinical Trials Scenario
2. Personalized Cancer Vaccine Mechanism of Action
2.1 Entities Involved in Personalized Cancer Vaccine and Their Respective Contributions 2.1.1 Tumor Neo - Antigens 2.1.2 Human Leukocyte Antigen 2.2 General Working of Personalized Cancer Vaccine 2.3 Genetic Polymorphism Leading to Pharmacogenomics 2.4 Cancer Pharmacogenomics Observing Somatic Mutations
3. Biomarkers Importance In Personalized Vaccines
3.1 Pharmacogenomic Biomarkers 3.2 Prognostic and Predictive Biomarkers
4. Ongoing Clinical Trials on Personalized Medicines
4.1 NEO-PV-01 Showing Glimmers of Success against Melanoma 4.2 Personalized Vaccine: An Evolving Biological Discovery for Pancreatic Cancer 4.3 Precision Cancer Vaccine against Metastatic Colorectal Cancer 4.4 First-in-Human Trial of Personalized Vaccine for Glioblastoma (Brain Tumor) 4.5 TG4001 in Combination with Avelumab against HPV Cancers
6. Personalized Cancer Vaccine: Manufacturing Process and Cost Analysis Study
6.1 Pre - Manufacturing Cost Analysis 6.2 Segmented Cost Analysis of Personalized Cancer Vaccine 6.2.1 Capital Cost 6.2.2 Cost of Raw Materials 6.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture 6.2.4 Factory and Administrative Overheads 6.2.5 Filling and Packaging 6.3 Per Patient Cost
7. Current Market Trends and Advancements in the Personalized Cancer Vaccine Segment
7.1 Researchers Improving the Outcome of Future Personalized Cancer Vaccine 7.2 Increasing Investments 7.3 Personalized Cancer Vaccine Development using mRNA 7.4 Personalized Cancer Vaccine Market Receiving Collaborations and Ventures Ensure Stable Funding 7.5 DNA Sequencing Technology Development Driving the Personalized Cancer Vaccine Market
8. Global - Personalized Cancer Vaccine Market Segmentation by Cancer Type
8.1 Personalized Cancer Vaccine Breakthrough against Melanoma 8.2 Lung Cancer Prevention using Personalized Vaccines 8.3 Personalized Cancer Vaccines towards Eliminating Breast Cancer 8.4 Colorectal Cancer Eradication by Personalized Cancer Vaccines 8.5 Scope of Leukemia Treatment using Personalized Cancer Vaccines 8.6 Prostate Cancer Eradication using Personalized Cancer vaccine: Provenge 8.7 Personalized Cancer Vaccines Targeting Cervical Cancer 8.8 Personalized Cancer Vaccines Application towards Glioblastoma (Brain Tumor)
9. Personalized Cancer Vaccine: Rising with New Avenues and Opportunities
9.1 Insights into the Personalized Cancer Vaccine Clinical Pipeline 9.2 Opportunities for Personalized Cancer Vaccine in the Emerging Market of the World
10. Porter’s Five Force Analysis of the Personalized Cancer Vaccine Market
10.1 Bargaining Power of Suppliers 10.2 Bargaining Power of Buyer 10.3 Threats of Substitute Products 10.4 Threat of New Entrants to the already Existing Market 10.5 Rivalry Among the Existing Competitors
11. Factors Driving the Market of Personalized Cancer Vaccine
11.1 Increased Demand for Personalized Cancer Vaccine Production 11.2 Increase Prevalence of Cancer Cases in the Population Worldwide 11.3 Cancer Heterogenetic Environment 11.4 High Level of Specificity 11.5 Assistance from Government 11.6 Advancements in Genome Sequencing Techniques Delivering better Personalized Cancer Vaccines 11.7 Robust Clinical Pipeline Under Development
12. Challenges Associated with Personalized Cancer Vaccine Market
12.1 Scientific and Technical Challenges in Developing a Personalized Cancer Vaccine 12.2 Commercial Challenges Surrounding Personalized Cancer Vaccines
13. Global Personalized Cancer Vaccine Market Future Outlook
14. Personalized Medicine Current Market Region Scenario
14.1 North America 14.2 Latin America 14.3 Europe 14.4 Asia-Pacific 14.4.1 Japan 14.4.2 India 14.4.3 South Korea 14.4.4 Taiwan 14.5 Middle East and Africa
15. Global Personalized Vaccine Trends
16. Competitive Landscape
16.1 Advaxis Inc. 16.2 Avax Technologies 16.3 BioNtech AG 16.4 Celldex 16.5 CureVac AG 16.6 Genetech 16.7 Genocea 16.8 Gristone Oncology 16.9 ISA Pharmaceuticals 16.10 Merck 16.11 Moderna Therapeutics 16.12 Neon Therapeutics 16.13 Personalis
Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo andndash; Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological and Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 4-1: Ongoing Clinical Trials on Personalized Vaccines
Figure 5-1: High Throughput Immune Assessment for Biomarker Discovery
Figure 6-1: General Overview of Personalized Cancer Vaccine Production
Figure 6-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 6-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
Figure 6-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
Figure 6-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
Figure 6-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
Figure 6-7: Gardasil andndash; Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 6-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 13-2: Gardasil/ Gardasil 9 Sales - US v/s Rest of World (US$ Billion), 2018
Figure 13-3: Gardasil/ Gardasil 9 - Global Patent Insight
Figure 13-4: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2019 andndash; 2026
Figure 14-1: US andndash; Total Cancer Deaths, 2016 - 2018
Figure 14-2: Europe andndash; Total Cancer Deaths, 2016 - 2018
Figure 14-3: Asia-Pacific andndash; Total Cancer Deaths, 2018
Figure 14-4: Japan andndash; Total Cancer Deaths, 2016 and 2018
Figure 14-5: India andndash; Total Cancer Deaths, 2014 and 2018
Figure 14-6: South Korea andndash; Total Cancer Deaths, 2014 - 2016
Figure 14-7: Taiwan - Total Cancer Deaths, 2017 andndash; 2018
Table 8-1:Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 8-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.